Mellitus ^Companies

Mellitus develops a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis, and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarker called Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts.